Vident Investment Advisory’s Genmab GMAB Stock Holding History

Vident Investment Advisory’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,842	Closed	-$298K	–	417
2023 Q2	$298K	Sell	7,842 -13,772	-64%	-$549K	0.01%	881
2023 Q1	$816K	Buy	21,614 +981	+5%	+$37.7K	0.03%	590
2022 Q4	$874K	Sell	20,633 -3,708	-15%	-$153K	0.03%	520
2022 Q3	$726K	Sell	24,341 -1,231	-5%	-$43.2K	0.02%	680
2022 Q2	$830K	Sell	25,572 -5,262	-17%	-$170K	0.02%	687
2022 Q1	$1.11M	Buy	30,834 +5,340	+21%	+$183K	0.03%	647
2021 Q4	$1.01M	Sell	25,494 -7,922	-24%	-$330K	0.03%	704
2021 Q3	$1.46M	Sell	33,416 -2,377	-7%	-$107K	0.04%	555
2021 Q2	$1.46M	Sell	35,793 -6,260	-15%	-$242K	0.04%	534
2021 Q1	$1.38M	Hold	42,053	–	–	0.05%	519
2020 Q4	$1.71M	Buy	+42,053	New	+$1.57M	0.07%	346

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vident Investment Advisory's GMAB Position: Q3 2023 in Review

Vident Investment Advisory sold out of Genmab (GMAB) in Q3 2023, closing a stake of 7,842 shares — an estimated $298K sold.

Vident Investment Advisory first reported a position in GMAB in Q4 2020 and held it in 11 quarters. The position peaked at $1.71M in Q4 2020. 233 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

Vident Investment Advisory reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 7,842 Genmab shares in Q3 2023, an estimated $298K.
Vident Investment Advisory first reported a position in Genmab in Q4 2020 and held it in 11 quarters.
Vident Investment Advisory's Genmab position peaked at $1.71M in Q4 2020.
233 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.